東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Case Studies in Modern Drug Discover...

Huang, Xianhai.

FindBook

Google Book

Amazon

博客來

Case Studies in Modern Drug Discovery and Development

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Case Studies in Modern Drug Discovery and Development/
作者:	Huang, Xianhai.
其他作者:	Aslanian, Robert G.
出版者:	Hoboken :John Wiley & Sons, : 2012.,
面頁冊數:	1 online resource (480 p.)
附註:	Wiley online library (ebook collection)
內容註:	CASE STUDIES IN MODERN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; CHAPTER 1: INTRODUCTION: DRUG DISCOVERY IN DIFFICULT TIMES; CHAPTER 2: DISCOVERY AND DEVELOPMENT OF THE DPP-4 INHIBITOR JANUVIA; (SITA-GLIPTIN); 2.1 Introduction; 2.2 DPP-4 Inhibition as a Therapy for Type 2 Diabetes: Identification of Key Determinants for Efficacy and Safety; 2.2.1 Incretin-Based Therapy for T2DM; 2.2.2 Biological Rationale: DPP-4 is a Key Regulator of Incretin Activity; 2.2.3 Injectable GLP-1 Mimetics for the Treatment of T2DM.
內容註:	2.2.4 DPP-4 Inhibition as Oral Incretin-Based Therapy for T2DM2.2.5 Investigation of DPP-4 Biology: Identification of Candidate Substrates; 2.2.6 Preclinical Toxicities of In-Licensed DPP-4 Inhibitors; 2.2.7 Correlation of Preclinical Toxicity with Off-Target Inhibition of Pro-Specific Dipeptidase Activity; 2.2.8 Identification of Pro-Specific Dipeptidases Differentially Inhibited by the Probiodrug Compounds; 2.2.9 A Highly Selective DPP-4 Inhibitor is Safe and Well Tolerated in Preclinical Species; 2.2.10 A Highly Selective DPP-4 Inhibitor Does Not Inhibit T-Cell Proliferation in vitro.
內容註:	2.2.11 DPP-4 Inhibitor Selectivity as a Key Parameter for Drug Development2.3 Medicinal Chemistry Program; 2.3.1 Lead Generation Approaches; 2.3.2 Cyclohexyl Glycine a-Amino Acid Series of DPP-4 Inhibitors; 2.3.3 Improving Selectivity of the a-Amino Acid Series; 2.3.4 Identification and Optimization of the ß-Amino Acid Series; 2.4 Synthetic and Manufacturing Routes to Sitagliptin; 2.4.1 Medicinal Chemistry Route to Sitagliptin and Early Modifications; 2.4.2 An Asymmetric Hydrogenation Manufacturing Route to Sitagliptin.
內容註:	2.4.3 A "Greener" Manufacturing Route to Sitagliptin Employing Biocatalytic Transamination2.5 Drug Product Development; 2.5.1 Overview; 2.5.2 Composition Development; 2.5.3 Manufacturing Process Development; 2.6 Clinical Studies; 2.6.1 Preclinical PD Studies and Early Clinical Development of Sitagliptin; 2.6.2 Summary of Phase II/III Clinical Trials; 2.7 Summary; References; CHAPTER 3: OLMESARTAN MEDOXOMIL: AN ANGIOTENSIN II RECEPTOR BLOCKER; 3.1 Background; 3.1.1 Introduction; 3.1.2 Prototype of Orally Active ARBs; 3.2 The Discovery of Olmesartan Medoxomil (Benicar); 3.2.1 Lead Generation.
內容註:	3.2.2 Lead Optimization3.3 Characteristics of Olmesartan; 3.4 Binding Sites of Omlersartan to the AT1 Receptor and Its Inverse Agonoist Activity; 3.4.1 Binding Sites of Olmesartan to the AT1 Receptor; 3.4.2 Inverse Agonist Activity of Olmesartan; 3.4.3 Molecular Model of the Interaction between Olmesartan and the AT1 Receptor; 3.5 Practical Preparation of Olmesartan Medoxomil; 3.6 Preclinical Studies; 3.6.1 AT1 Receptor Blocking Action; 3.6.2 Inhibition of Ang II-Induced Vascular Contraction; 3.6.3 Inhibition of the Pressor Response to Ang II; 3.6.4 Blood Pressure Lowering Effects.
標題:	Drug development. -
電子資源:	http://dx.doi.org/10.1002/9781118219683
ISBN:	9781118219706 (electronic bk.)

Case Studies in Modern Drug Discovery and Development
Huang, Xianhai.

Case Studies in Modern Drug Discovery and Development[electronic resource]. - Hoboken :John Wiley & Sons,2012. - 1 online resource (480 p.)

Wiley online library (ebook collection)

CASE STUDIES IN MODERN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; CHAPTER 1: INTRODUCTION: DRUG DISCOVERY IN DIFFICULT TIMES; CHAPTER 2: DISCOVERY AND DEVELOPMENT OF THE DPP-4 INHIBITOR JANUVIA; (SITA-GLIPTIN); 2.1 Introduction; 2.2 DPP-4 Inhibition as a Therapy for Type 2 Diabetes: Identification of Key Determinants for Efficacy and Safety; 2.2.1 Incretin-Based Therapy for T2DM; 2.2.2 Biological Rationale: DPP-4 is a Key Regulator of Incretin Activity; 2.2.3 Injectable GLP-1 Mimetics for the Treatment of T2DM.

Learn why some drug discovery and development efforts succeed ... and others failWritten by international experts in drug discovery and development, this book sets forth carefully researched and analyzed case studies of both successful and failed drug discovery and development efforts, enabling medicinal chemists and pharmaceutical scientists to learn from actual examples. Each case study focuses on a particular drug and therapeutic target, guiding readers through the drug discovery and development process, including drug design rationale, structure-activity relationships, pharmacology, drug.

ISBN: 9781118219706 (electronic bk.)

Source: 10.1002/9781118219683Wiley InterSciencehttp://www3.interscience.wiley.comSubjects--Topical Terms:

716904
Drug development.

LC Class. No.: QV744

Dewey Class. No.: 615.19

Case Studies in Modern Drug Discovery and Development
LDR:04755cmm a2200385 u 4500 001 1920241
003 OCoLC
005 20130505100317.0
006 m o d
008 140523s2012 xx o 000 0 eng d
019 $a 795813847
020 $a 9781118219706 (electronic bk.)
020 $a 1118219708 (electronic bk.)
020 $a 9781118219683 (electronic bk.)
020 $a 1118219686 (electronic bk.)
037 $a 10.1002/9781118219683 $b Wiley InterScience $n http://www3.interscience.wiley.com
040 $a EBLCP $b eng $c EBLCP $d OCLCQ $d IDEBK $d N $d DG1 $d OCLCO $d YDXCP $d OCLCQ
050 # 4 $a QV744
072 7 $a MED $x 023000 $2 bisacsh
072 7 $a MED $x 058170 $2 bisacsh
072 7 $a MED $x 071000 $2 bisacsh
072 7 $a MED $x 072000 $2 bisacsh
082 0 4 $a 615.19
100 1 $a Huang, Xianhai. $3 2045384
245 1 0 $a Case Studies in Modern Drug Discovery and Development $h [electronic resource].
260 # $a Hoboken : $b John Wiley & Sons, $c 2012.
300 $a 1 online resource (480 p.)
500 $a Wiley online library (ebook collection)
505 0 # $a CASE STUDIES IN MODERN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; CHAPTER 1: INTRODUCTION: DRUG DISCOVERY IN DIFFICULT TIMES; CHAPTER 2: DISCOVERY AND DEVELOPMENT OF THE DPP-4 INHIBITOR JANUVIA; (SITA-GLIPTIN); 2.1 Introduction; 2.2 DPP-4 Inhibition as a Therapy for Type 2 Diabetes: Identification of Key Determinants for Efficacy and Safety; 2.2.1 Incretin-Based Therapy for T2DM; 2.2.2 Biological Rationale: DPP-4 is a Key Regulator of Incretin Activity; 2.2.3 Injectable GLP-1 Mimetics for the Treatment of T2DM.
505 8 # $a 2.2.4 DPP-4 Inhibition as Oral Incretin-Based Therapy for T2DM2.2.5 Investigation of DPP-4 Biology: Identification of Candidate Substrates; 2.2.6 Preclinical Toxicities of In-Licensed DPP-4 Inhibitors; 2.2.7 Correlation of Preclinical Toxicity with Off-Target Inhibition of Pro-Specific Dipeptidase Activity; 2.2.8 Identification of Pro-Specific Dipeptidases Differentially Inhibited by the Probiodrug Compounds; 2.2.9 A Highly Selective DPP-4 Inhibitor is Safe and Well Tolerated in Preclinical Species; 2.2.10 A Highly Selective DPP-4 Inhibitor Does Not Inhibit T-Cell Proliferation in vitro.
505 8 # $a 2.2.11 DPP-4 Inhibitor Selectivity as a Key Parameter for Drug Development2.3 Medicinal Chemistry Program; 2.3.1 Lead Generation Approaches; 2.3.2 Cyclohexyl Glycine a-Amino Acid Series of DPP-4 Inhibitors; 2.3.3 Improving Selectivity of the a-Amino Acid Series; 2.3.4 Identification and Optimization of the ß-Amino Acid Series; 2.4 Synthetic and Manufacturing Routes to Sitagliptin; 2.4.1 Medicinal Chemistry Route to Sitagliptin and Early Modifications; 2.4.2 An Asymmetric Hydrogenation Manufacturing Route to Sitagliptin.
505 8 # $a 2.4.3 A "Greener" Manufacturing Route to Sitagliptin Employing Biocatalytic Transamination2.5 Drug Product Development; 2.5.1 Overview; 2.5.2 Composition Development; 2.5.3 Manufacturing Process Development; 2.6 Clinical Studies; 2.6.1 Preclinical PD Studies and Early Clinical Development of Sitagliptin; 2.6.2 Summary of Phase II/III Clinical Trials; 2.7 Summary; References; CHAPTER 3: OLMESARTAN MEDOXOMIL: AN ANGIOTENSIN II RECEPTOR BLOCKER; 3.1 Background; 3.1.1 Introduction; 3.1.2 Prototype of Orally Active ARBs; 3.2 The Discovery of Olmesartan Medoxomil (Benicar); 3.2.1 Lead Generation.
505 8 # $a 3.2.2 Lead Optimization3.3 Characteristics of Olmesartan; 3.4 Binding Sites of Omlersartan to the AT1 Receptor and Its Inverse Agonoist Activity; 3.4.1 Binding Sites of Olmesartan to the AT1 Receptor; 3.4.2 Inverse Agonist Activity of Olmesartan; 3.4.3 Molecular Model of the Interaction between Olmesartan and the AT1 Receptor; 3.5 Practical Preparation of Olmesartan Medoxomil; 3.6 Preclinical Studies; 3.6.1 AT1 Receptor Blocking Action; 3.6.2 Inhibition of Ang II-Induced Vascular Contraction; 3.6.3 Inhibition of the Pressor Response to Ang II; 3.6.4 Blood Pressure Lowering Effects.
520 # $a Learn why some drug discovery and development efforts succeed ... and others failWritten by international experts in drug discovery and development, this book sets forth carefully researched and analyzed case studies of both successful and failed drug discovery and development efforts, enabling medicinal chemists and pharmaceutical scientists to learn from actual examples. Each case study focuses on a particular drug and therapeutic target, guiding readers through the drug discovery and development process, including drug design rationale, structure-activity relationships, pharmacology, drug.
588 $a Description based on print version record.
650 # 0 $a Drug development. $3 716904
650 # 0 $a Medicine. $3 641104
650 # 0 $a Pharmacy. $3 636101
650 # 7 $a MEDICAL / Drug Guides $2 bisacsh $3 1614336
650 # 7 $a MEDICAL / Nursing / Pharmacology $2 bisacsh $3 1614337
650 # 7 $a MEDICAL / Pharmacology $2 bisacsh $3 1614338
650 # 7 $a MEDICAL / Pharmacy $2 bisacsh $3 1614339
650 # 4 $a Drug Discovery. $3 1359836
650 # 4 $a Drug Evaluation. $3 550959
700 1 # $a Aslanian, Robert G. $3 2045385
776 0 8 $i Print version: $a Huang, Xianhai $t Case Studies in Modern Drug Discovery and Development $d Hoboken : John Wiley & Sons, c2012 $z 9780470601815
856 4 0 $u http://dx.doi.org/10.1002/9781118219683